TEK2day FINANCE Open Terminal →

Hypera S.A. (HYPMY)

OID · Healthcare · Drug Manufacturers - Specialty & Generic

$4.13 +2.23%

Closing price as of 2026-06-12 · Source: TEK2day Finance

1-Year Price History -12.9% over period
$5$5$4$4$4 2025-062025-092025-122026-032026-06

Key Metrics

Market Cap
$2.91B
Shares Outstanding
704.0M
P/S (TTM)
nanx
P/E (TTM)
1.6x
Exchange
OID
Currency
USD

About Hypera S.A.

Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Coristina, APRACUR, and Fluviral brands. It offers antihistamines products under Alektos, Histamin, Polaramine, PredSim, and Desrinite brands; antiseptics products under Merthiolate brand; Herbal medicine products under Maracugina, Eparema, Tamarine, and Naturetti brands; gastrointestinal products under Dramin, Estomazil, Engov, Lacto-purga, gastrol, Epocler, Bifilax, and Pepsamar brands. In addition, the company provides generics products under neo quimica brand; skicare products under episol, epidrat, simple organic, and bioage brands; supplements and vitamins products Addera, Biotonico Fontoura, Colflex, and Vitasay brands; and other products under Nebacetin, Cepacol, ESCABIN, Mirrorelax, Ammy, Nesina, and Diprospan brands. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 1999 and is headquartered in São Paulo, Brazil.

Quarterly Financials

Metric2025-06-302025-09-302025-12-312026-03-31
Revenue2.2B2.2B2.0B
Gross Profit1.3B1.4B1.2B
Operating Income643.3M650.3M505.9M
Net Income426.7M451.0M347.4M
Diluted EPS$0.66$0.71$0.70$0.54

Annual Financials

Metric2022-12-312023-12-312024-12-312025-12-31
Revenue7.5B7.9B7.4B7.7B
Gross Profit4.8B5.0B4.4B4.5B
Operating Income2.5B2.5B1.8B1.7B
Net Income1.7B1.6B1.3B1.2B
Diluted EPS$2.63$2.56$2.06$1.87
Want live quotes, estimates, SEC filings, and CEO analytics for HYPMY?
The free TEK2day terminal runs in your browser — type /HYPMY to get started.
Open HYPMY in the Terminal →